Skip to main content

Virpax Pharmaceuticals prices $40M public stock offering

The company plans to use the proceeds to advance its non-opioid and non-addictive pain management products.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.